The metabolic field's consensus by 2021 was that you want to agonize both GLP-1 and GIP. US10905772B2 - "Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)," issued February 2, 2021 to Amgen Inc. - claims the contrarian bet: agonize GLP-1, but block GIP.

The scientific divergence is the headline, but the claim's enforceable spine is the conjugation, and claim 1 specifies it with antibody-engineering precision. The claim recites a composition comprising (a) an antibody or fragment that specifically binds human GIPR, defined down to six exact CDR sequences (the CDRL1/2/3 and CDRH1/2/3 given as named SEQ ID NOs), and bearing a cysteine or non-canonical amino acid substitution at one or more conjugation sites; and (b) a GLP-1 receptor agonist conjugated to that antibody through the side-chain of the cysteine or non-canonical residue. So the construct is a single molecule that pairs GLP-1 agonism with GIPR antagonism, and the way the two are joined - site-specific conjugation through an engineered cysteine - is written into the independent claim.

"Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided."- U.S. Patent No. 10,905,772 source

The dependent claims disclose the engineering choices that make such a conjugate manufacturable. Claims 10-13 name the exact conjugation sites - D70 on the light chain, E276 and T363 on the heavy chain, each defined against a reference sequence - the engineered cysteines where the payload attaches; this is the disclosed mechanism for a homogeneous, site-specific conjugate rather than a randomly decorated antibody. Claim 9 specifies that the antibody inhibits binding of GIP to the extracellular portion of GIPR, i.e. it is a true antagonist of the receptor. Claims 14-17 enumerate the GLP-1 agonist payload - GLP-1(7-37) and its analogs, and a long roster of exendin-4-based and acylated peptides including liraglutide, dulaglutide, semaglutide, and many sequence-defined variants. Claim 18 lists the peptide linkers (Gly3Ser and Gly4Ser repeats) that bridge payload to antibody. The CPC tags capture both halves: A61K 47/6849 and A61K 47/6803 (antibody-conjugate chemistry), C07K 16/28 and C07K 16/2869 (the anti-receptor antibody).

Why does the conjugation limitation decide scope? Because the inventive claim is not 'antagonize GIP' in the abstract - prior art on GIPR antagonism exists - but the specific construct that delivers GLP-1 agonism and GIPR antagonism together, joined through defined engineered-cysteine sites, with a sequence-defined antibody and an enumerated payload. A competitor administering two separate agents, using an antibody with different CDRs, or conjugating at non-claimed sites might fall outside claim 1 as written. The precision of the CDR and conjugation-site definitions is what gives the claim a hard, checkable boundary.

This is also a clean illustration of why mechanism alone never tells you claim scope. Amgen's approach (this construct underpins what became its maritide / AMG 133 program) and Lilly's dual-agonist tirzepatide point in opposite pharmacological directions on GIP, yet both can hold valid patents because each claims its own specific construct, not the mechanism in the abstract.

The CDR definition in claim 1 is the structural backbone that makes the rest checkable. By reciting all six complementarity-determining regions as named SEQ ID NOs (CDRL1-3 and CDRH1-3), the claim ties infringement to a specific antibody's binding loops, not to anti-GIPR antibodies as a class. Claims 10 and 12 extend that specificity to full light- and heavy-chain and variable-region sequences. The effect is that an accused antibody must share these defined loops to read on the claim - a much harder standard to meet by independent discovery than a functional "binds GIPR" limitation would be, and a much easier one to adjudicate.

The conjugation-site claims are the other half of the structural story and disclose a real manufacturing mechanism. Claims 10, 11, and 13 name engineered attachment points - D70 on the light chain, E276 and T363 on the heavy chain, each defined against a reference sequence - where a cysteine or non-canonical amino acid is substituted in. Site-specific conjugation through engineered cysteines produces a homogeneous product with a controlled drug-to-antibody ratio, in contrast to the heterogeneous mixtures that result from conjugating to native surface lysines or cysteines. That homogeneity is a quality and regulatory advantage, and by claiming the specific sites, the patentee protects the manufacturable form of the molecule rather than the abstract idea of attaching a GLP-1 agonist to an anti-GIPR antibody.

The payload breadth in claims 14-17 is the counterweight to that structural precision. The GLP-1 agonist can be GLP-1(7-37), its analogs, or any of a long list of exendin-4-derived and acylated peptides - liraglutide, dulaglutide, semaglutide, taspoglutide, and many sequence-defined variants. So the antibody and conjugation chemistry are pinned down tightly while the agonist payload is allowed to range widely, with the Gly-Ser linkers of claim 18 bridging the two. For a teardown, that asymmetry is the design signature: the inventive contribution is concentrated in the specific antagonist antibody and its engineered conjugation sites, and the payload list is drawn broadly so a competitor cannot escape merely by swapping one well-known GLP-1 agonist for another.

For the landscape, the grant marks the metabolic estate branching into incompatible hypotheses - agonize-GIP versus antagonize-GIP - each separately patented. A freedom-to-operate read for any GIP-targeting program has to check both branches, because the prior art now runs in two directions, and because a conjugate claim this specific is navigated by its named CDRs, conjugation sites, and payload list rather than by its therapeutic rationale.